Navigation Links
CuraGen Announces Top-Line Phase II Results on Velafermin

Tuesday, October 23, 2007

Poster Board: A68

Session: Poster Session A: Biological Therapeutic Agents

Upcoming Presentations at the 2007 ASH Annual Meeting, December 8-11, 2007 in Atlanta, GA:


Title: Belinostat (PXD101) in Patients with Recurrent or

Refractory Peripheral or Cutaneous T-Cell Lymphoma:

Results of a Phase II Study

Date: Monday, December 10, 2007

Poster Board: 2607

Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models:

Diffuse Large Cell Lymphoma and T-Cell Lymphoma


Title: A Randomized Placebo Controlled Phase II Trial of

Prevention of Severe Oral Mucositis Using Single Dose

Velafermin in Patients Receiving Myeloablative Therapy and

Autologous Hematopoietic Stem Cell Transplant (AHSCT)

Date: December 10, 2007

Time: 4:00 p.m. Eastern Time

Session: Clinical Care: Transplantation Regimen Toxicities and

Engraftment-Regimen-Related Toxicities

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... (OTCQB: CNBX) has announced its execution of an Intellectual Property ... Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related party, ... --> --> These ... of the Company, whereby the Research and Development components ...
(Date:10/9/2015)... 2015  The Centers for Disease Control and ... Zoonotic Infectious Diseases, Office of Advanced Molecular Detection ... research collaboration to evaluate the performance of Edico ... research collaboration is to evaluate the utility of ... and infectious disease applications. This collaboration will also ...
(Date:10/9/2015)... Texas , Oct. 9, 2015   Lexicon Pharmaceuticals, ... from the TELESTAR Phase 3 clinical study of telotristat etiprate ... Tumor Society annual symposium to be held from October 15-17, ... from interviews with patients who completed the randomized treatment portion ... time in a poster session. --> ...
Breaking Medicine Technology:
... Conn., Feb. 14, 2012  UBM Medica,s MusculoskeletalNetwork ... updates on management of musculoskeletal disorders, now features a ... 2012 Annual Meeting of the American Academy of Orthopaedic ... California. The AAOS conference offers orthopedists a ...
... professional athletes are not the only people who are ... Physicians are often paid for their signature too – ... employment contract. (Logo: ) ... an average of more than $20,000 to sign on ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... "As a nurse, I care for male patients ... have to wear large diapers or pads. We came up with this as a ... absorb urine leaking from the tip of the penis. This prevents stains from forming ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental ... teenagers facing mental illness, the stigma associated with mental illness causes many to hide ... understands the importance of supporting teens with mental illness , providing teens with ...
(Date:10/9/2015)... ... October 09, 2015 , ... Deadly, record-smashing rainfall ... Community Foundation (CCCF) in Columbia, South Carolina. In response, the Foundation has established ... victims – both short and long term. 100% of monies donated will go ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smanos was featured on NewsWatch as part ... to consumers. Scott Steinberg, a technology expert and special reporter for NewsWatch, conducted the ... or dorm. , In this day and age it’s more important than ever to ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Kitchenistas ... struggling against diabetes, obesity, and other health conditions related to food, has been selected ... City and at the Global Health Film Festival on October 30-31 in London, England. ...
Breaking Medicine News(10 mins):
... The Health Coalition on Liability and Access released ... reform on the state and federal level. The report ... have passed laws limiting non-economic damages, while also acknowledging ... yet to be enacted and is unlikely in the ...
... Impaired Driving Experience(R), (SIDNE(R)), will be availableNASHVILLE, March 27 ... at the Gaylord Opryland Resort and Convention Center this ... Conference is a national traffic safety conference that aims ... "We are excited to demonstrate our new tools and ...
... Zydus Pharmaceuticals announced today that it has received ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... This product is available for immediate shipment.Topiramate tablets are ... old or older with partial onset or primary generalized ...
... Young Women Expected for 35 Progressive Workshops, Including ... Pa., March 27 The following release was ... ) ... a.m. to 3 p.m.WHERE: Springside School for ...
... CHICAGO, March 27 A panel of leading ... days earlier this month in Beverly Hills to ... presentations surrounding the most massive of toxic torts.The ... are now available from HB Litigation Conferences LLC, ...
... Following the success of a program established in Uganda ... Health Volunteers Overseas (HVO) have again partnered to launch ... Security Health System, Empresa De Seguros De Salud (EsSalud). ... hematology training of clinicians, laboratory technicians, technologists, and students. ...
Cached Medicine News:
Micro 2000 suture forceps light-weight instruments with blue-colored anodized round handles, extremely light weight, well balanced, easy to handle, fatigueless working, easy to maintain, corrosion-re...
Micro suture forceps....
30 Degree angle....
Operating microscope with motorized zoom and variable focus up to 405 mm....
Medicine Products: